Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Equity Income (2021 - 2023)

Historic Equity Income for ImmunityBio (IBRX) over the last 3 years, with Q3 2023 value amounting to -$1.3 million.

  • ImmunityBio's Equity Income rose 7183.57% to -$1.3 million in Q3 2023 from the same period last year, while for Jun 2024 it was -$1.3 million, marking a year-over-year increase of 9122.62%. This contributed to the annual value of -$7.5 million for FY2023, which is 3764.76% up from last year.
  • As of Q3 2023, ImmunityBio's Equity Income stood at -$1.3 million, which was up 7183.57% from -$4.0 million recorded in Q2 2023.
  • In the past 5 years, ImmunityBio's Equity Income registered a high of -$197000.0 during Q1 2022, and its lowest value of -$4.5 million during Q3 2022.
  • In the last 3 years, ImmunityBio's Equity Income had a median value of -$2.9 million in 2022 and averaged -$2.6 million.
  • The largest annual percentage gain for ImmunityBio's Equity Income in the last 5 years was 7183.57% (2023), contrasted with its biggest fall of 108629.44% (2023).
  • ImmunityBio's Equity Income (Quarter) stood at -$803000.0 in 2021, then crashed by 342.59% to -$3.6 million in 2022, then skyrocketed by 64.69% to -$1.3 million in 2023.
  • Its last three reported values are -$1.3 million in Q3 2023, -$4.0 million for Q2 2023, and -$2.3 million during Q1 2023.